How safe is MP1032? And why is that so important to us?
Our Phase II clinical trial in psoriasis is almost completed. And we are especially interested in one question: Has the good safety profile from our previous studies been confirmed? Nobody wants avoidable side effects. But does it really make sense that we place so much emphasis on a good safety profile in the development of MP1032?
The connection between chronic inflammation and diseases of aging
Is there a
problem with increasing life expectancy? If you look at the graph of average
life years alone, the development over the last fifty years looks very
positive. This graph shows a steady upward trend, especially in Western
countries. People are getting older continuously.
There is, however, a second graph that has risen much slower: that of healthy life expectancy...
A report on the current projects of the MetrioPharm team
Timetables on the office
walls, e-mails with long to-do lists and meetings of all project groups: The
new year has started off busy. In order to move the MetrioPharm pipeline ahead
as planned, the team is coordinating several major projects simultaneously.
One of the most important is the completion of the Phase II trial in the indication psoriasis...
In October you attended the ECTRIMS conference for MetrioPharm. What was your impression?
Dr. Sara Schumann: The conference is immense. This year there were more than 9000 participants who met in Berlin. One can say that this international conference is the most important forum for researchers and clinicians on multiple sclerosis (MS).
Dr. Astrid Kaiser: Many MS therapies already available today were presented. Of course, we can learn a lot from these post-marketing studies as they clearly show the advantages and disadvantages of currently available drugs.
We have spent this summer on the road. While the scientific team oversaw the progress of our Phase II clinical trial, our Business Development and Investor Relations staff introduced MetrioPharm AG to many different people: potential development partners, medical scientists, financial analysts, healthcare experts and investors.
MetrioPharm’s lead compound MP1032 entered Phase II clinical testing in early March. How has the study gone so far?
Dr. Petra Schulz: The most important goal of a large Phase II study continues to be to test the safety of the drug, i.e. whether the patients tolerate it well. So far, nobody has had to discontinue the study after taking MP1032, which is a good signal. The other important objectives – proof of efficacy and the search for the optimal dosage – are still unknown, because at the moment the study is blinded.